A new once-a-day pill that acts like 'Viagra for the brain' has been shown to slow clinical decline in Alzheimer's patients by a third.The blockbuster therapy delayed progression of the disease by the equivalent of 3.5 months after just one year in a major phase III trial.Participants given the drug, known as AR1001 and made by South Korean pharmaceutical firm AriBio, performed 31 per cent better in an assessment of memory, thinking and everyday functioning than those given a placebo.Results presented at the Clinical Trials on Alzheimer's Disease conference in Boston, United States, this evening suggest it is the first oral treatment to successfully target an underlying cause of the disease, rather than simply tackle symptoms.Other disease-modifying therapies, such as lecanemab and donanemab, have to be given by infusion in a clinic or by injection and have not been approved for use on the NHS because of the high cost of administering them.Having an alternative in tablet form could significantly lower the cost and provide an attractive option to people who dislike needles.The new drug's active ingredient, mirodenafil, belongs to the same class of drugs as sildenafil, which is found in Viagra and used to treat erectile dysfunction.They both work to block an enzyme called PDE5, which in turn relaxes blood vessels and increases blood flow. The new drug's active ingredient, mirodenafil, belongs to the same class of drugs as sildenafil, which is found in Viagra and used to treat erectile dysfunction. AR1001 is thought to have a number of beneficial effects in the brain, including lowering inflammation, increasing blood flow and protecting nerve cells.The global trial involved 1,535 people with Alzheimer's from 230 sites in 13 countries, including the United Kingdom.Researchers found the 31 per cent benefit among patients who were not taking any other dementia medications, known as the 'monotherapy' group.A lesser benefit of 7 per cent was found among those who took AR1001 alongside other dementia drugs but this was not considered statistically significant.AR1001 operates differently to existing disease-modifying treatments lecanemab and donanemab, which help remove amyloid plaque from the brain.Most side effects reported in the trial were mild or moderate, with the most common being diarrhoea, falls and dizziness.Some 69 per cent of people receiving AR1001 reported side effects, compared to 66.4 per cent receiving the placebo.AriBio also looked at markers of Alzheimer's disease in cerebrospinal fluid and found lower levels of ptau217, which is tested to identify the presence of both amyloid and tau - hallmarks of Alzheimer's in the brain.The findings come as the Daily Mail's Dementia Carers Together Appeal is raising money for new six-week courses for friends and relatives of people living with the disease.Delivered in partnership with Alzheimer's Society and the Mail Force charity, the sessions will give carers vital support and information about their rights and the services available to them.They will allow attendees to meet others in a similar situation and help to address the loneliness, exhaustion and overwhelming responsibilities many face following a loved one's diagnosis.Dr Richard Oakley, Associate Director for Research and Innovation at Alzheimer's Society, said: 'These topline results are an encouraging sign that we could have a new treatment for early Alzheimer's disease that tackles its causes, not just its symptoms.'Over the year of the trial, the drug was able to slow down people's decline in memory and thinking by nearly a third.'However, results were not apparent in people taking other drugs for Alzheimer's symptoms, so this needs further investigation.'AR1001 works differently from other disease-modifying treatments we've seen so far and, as a once-a-day tablet, could offer a simpler way for people to receive treatment. Reported side effects were mostly mild to moderate in severity.'This drug is from the same family of medicines as Viagra, but it is being developed specifically for Alzheimer's disease. People should not take Viagra to try to treat Alzheimer's.'It's important to note AR1001 is not yet available to the public and will need to be assessed and approved by UK regulatory bodies before it could be offered in the UK.'Research is making huge progress and will beat dementia – and as more potential treatments emerge, it's more important than ever that people get an early and accurate dementia diagnosis so they can benefit from them.'We look forward to seeing the full results from this trial and how this drug progresses.'Dr David Greeley, a leading clinical researcher in Alzheimer's drug development at Northwest Neurological, in the United States, said: 'As a practicing neurologist and clinical investigator for over thirty years - as well as an investigator for AriBio since Phase 2 - I see how urgently patients and families need treatments for Alzheimer's disease.'The findings in the pre-specified Monotherapy population of the AriBio study recently released are very encouraging and support the premise of a once-daily oral approach to this devastating disease.'If approved, this oral drug would broaden patients' options.'Further evaluation is needed, but our goal is meaningful treatment that not only helps patients but that can be realistically afforded, received and sustained.' Dementia Carers Together Dementia Carers Together is raising money to fund new courses across the UK to give tens of thousands of struggling unpaid dementia carers vital emotional and practical support. For further information, visit dailymail.com/dementiaHow you can donateOnline: Click here.By Text: To donate £10, text CARER to 70115. To donate £20, text LOVE to 70115. To donate £30, text HEART to 70115. Texts will cost your donation amount plus your network charge.By phone: Call 0300 1234577. Standard charges may apply.By cheque: Send cheques made payable to Mail Force Charity to:Dementia Carers Together, 42 Phoenix Court, Hawkins Road, Colchester CO2 8JY
New 'Viagra for the brain' pill slows clinical decline in Alzheimer's patients by a third
Full Article
Original Source
Read the full article at Dailymail →KhanList aggregates and links to publicly available news content. We do not host full articles from third-party sources. Always verify important information with original sources.